The potential of nanogels derived from C. comatus mushrooms has demonstrated effectiveness as anti-arthritis and anti-inflammatory agents by reducing pro-inflammatory cytokine levels and COX-2 enzyme activity, suppressing antibody levels in serum, and decreasing edema and arthritis in the feet of experimental animals. This evidence concerns the gene PTGS2 and arthritic joint disease.